WHITMORE BRADFORD T 13D and 13G filings for Clearside Biomedical, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-03-04 5:20 pm Purchase |
2024-12-31 | 13G | Clearside Biomedical, Inc. CLSD |
WHITMORE BRADFORD T | 6,523,511 8.600% |
258,547 (+4.13%) |
Filing |
| 2023-11-01 4:04 pm Purchase |
2023-10-27 | 13G | Clearside Biomedical, Inc. CLSD |
WHITMORE BRADFORD T | 6,264,964 10.100% |
247,112 (+4.11%) |
Filing |
| 2023-01-04 12:06 pm Purchase |
2022-12-31 | 13G | Clearside Biomedical, Inc. CLSD |
WHITMORE BRADFORD T | 6,017,852 9.900% |
139,655 (+2.38%) |
Filing |
| 2022-01-24 4:03 pm Sale |
2021-12-31 | 13G | Clearside Biomedical, Inc. CLSD |
WHITMORE BRADFORD T | 5,878,197 9.900% |
-486,989 (-7.65%) |
Filing |
| 2021-01-07 11:10 am Purchase |
2021-01-06 | 13G | Clearside Biomedical, Inc. CLSD |
WHITMORE BRADFORD T | 6,365,186 11.100% |
929,845 (+17.11%) |
Filing |